Long Unsuccessful Heart Failure Drug Once Again At Center Of Controversy

–The long, strange 30-year journey of BiDil. It’s been buried in the avalanche of related news but there’s an interesting and somewhat bizarre cardiology angle to the debate over Trump’s nomination of Tom Price to be the next HHS Secretary. ProPublica reported on Friday that last summer Price went to bat for the makers of...Click here to continue reading...

Source: CardioBrief - January 23, 2017 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Uncategorized ACE inhibitors BiDil conflict of interest HHS Tom Price Source Type: blogs